Furthermore, phase I and II trials of anti-PD-1 or anti-PD-L1 therapy combined with CRT have shown promising responses in other cancer types, such as head and neck, pancreatic and colorectal cancer [3–5]. This evidence concerns the gene CD274 and cancer.